Ovarian Cancer Audit Feasibility Pilot (OCAFP) - Profile and treatment report

Report index

In 2020, the Ovarian Cancer Audit Feasibility Pilot (OCAFP) produced two reports that indicated regional disparities across England in both ovarian cancer survival ¹ and treatment delivery ². Together, these reports provided valuable learning for developing targeted improvements in clinical practice and improved outcomes for patients.

This latest report provides an update to these earlier statistics, reporting results for diagnoses up to the period immediately preceding the Covid-19 pandemic.

There is continued evidence of incidence remaining reasonably stable in England, and survival improving. However, variation in incidence, mortality rates and stage at diagnosis can be seen across sub-ICBs and Cancer Alliances. Additionally, marked geographic inequalities in access to treatment remain, even after accounting for regional differences in patient and tumour characteristics.

These refreshed findings provide a new opportunity for identifying recent examples of best practice that could be disseminated to areas where treatment rates and patient survival are poor comparative to national averages.

Notes:

1. National Cancer Registration and Analysis Service. Ovarian Cancer Audit Feasibility Pilot (OCAFP) - Disease Profile; 2020.
2. National Cancer Registration and Analysis Service. Ovarian Cancer Audit Feasibility Pilot (OCAFP) - Geographic Variation; 2020.